v3.26.1
Note 6 - Investments (Details Textual) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Sep. 30, 2021
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Schedule of Equity Method Investments [Line Items]            
Total revenues   $ 163,580 $ 156,807 $ 287,777 $ 306,759  
Assets   1,829,453   1,829,453   $ 1,931,944
Liabilities   645,287   645,287   663,985
Equity Method Investment, Quoted Market Value   300   300   200
Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member]            
Schedule of Equity Method Investments [Line Items]            
Assets   41,900   41,900   48,900
Liabilities   $ 17,000   17,000   17,500
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest       $ 6,400   $ 13,900
Nicoya Therapeutics Cayman [Member] | Series A-2 Preferred Stock [Member]            
Schedule of Equity Method Investments [Line Items]            
Minority Interest, Shares Issued (in shares)       20,500,000    
Subsidiary, Ownership Percentage, Parent   13.90%   13.90%    
Minority Interest Increase Ownership Percentage By Parent   15.00%   15.00%    
Entera Bio Ltd. [Member]            
Schedule of Equity Method Investments [Line Items]            
Equity Security, FV-NI, Ownership Percent   7.50%   7.50%    
ChromaDex Corporation [Member]            
Schedule of Equity Method Investments [Line Items]            
Equity Security, FV-NI, Ownership Percent   0.04%   0.04%    
Eloxx Pharmaceuticals, Inc. [Member]            
Schedule of Equity Method Investments [Line Items]            
Equity Security, FV-NI, Ownership Percent   1.00%   1.00%    
Xenetic Biosciences, Inc. [Member]            
Schedule of Equity Method Investments [Line Items]            
Equity Security, FV-NI, Ownership Percent   1.00%   1.00%    
CAMP4 Therapeutics Corporation [Member]            
Schedule of Equity Method Investments [Line Items]            
Equity Security, FV-NI, Ownership Percent   1.00%   1.00%    
HealthSnap, Inc. [Member]            
Schedule of Equity Method Investments [Line Items]            
Equity Security, FV-NI, Ownership Percent   4.00%   4.00%    
Zebra [Member]            
Schedule of Equity Method Investments [Line Items]            
Equity Method Investment, Ownership Percentage   29.00%   29.00%    
Zebra [Member] | Variable Interest Entity, Not Primary Beneficiary [Member] | Series A-2 Preferred Stock [Member]            
Schedule of Equity Method Investments [Line Items]            
Investment Owned, Balance, Shares (in shares)   1,260,000   1,260,000   1,260,000
Zebra [Member] | Variable Interest Entity, Not Primary Beneficiary [Member] | Restricted Stock [Member]            
Schedule of Equity Method Investments [Line Items]            
Investment Owned, Balance, Shares (in shares)   900,000   900,000   900,000
Equity Method Investment, Ownership Percentage   29.00%   29.00%   29.00%
BioCardia [Member]            
Schedule of Equity Method Investments [Line Items]            
Equity Security, FV-NI, Ownership Percent   0.13%   0.13%    
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)   47,000   47,000   47,000
Pharmsynthez [Member]            
Schedule of Equity Method Investments [Line Items]            
Equity Method Investment, Ownership Percentage   6.00%   6.00%    
COCP [Member]            
Schedule of Equity Method Investments [Line Items]            
Equity Method Investment, Ownership Percentage   2.00%   2.00%    
NIMS [Member]            
Schedule of Equity Method Investments [Line Items]            
Equity Method Investment, Ownership Percentage   1.00%   1.00%    
LeaderMed [Member]            
Schedule of Equity Method Investments [Line Items]            
Equity Method Investment, Ownership Percentage   47.00%   47.00%    
LeaderMed [Member] | LeaderMed Joint Venture [Member]            
Schedule of Equity Method Investments [Line Items]            
Minority Interest, Shares Issued (in shares) 4,703          
Subsidiary, Ownership Percentage, Parent 47.00%          
Total revenues $ 1,000